HRP970235B1 - Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl-6-chloro-1,3-dihydro-2h-indol-2-one - Google Patents

Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl-6-chloro-1,3-dihydro-2h-indol-2-one

Info

Publication number
HRP970235B1
HRP970235B1 HR970235A HRP970235A HRP970235B1 HR P970235 B1 HRP970235 B1 HR P970235B1 HR 970235 A HR970235 A HR 970235A HR P970235 A HRP970235 A HR P970235A HR P970235 B1 HRP970235 B1 HR P970235B1
Authority
HR
Croatia
Prior art keywords
benzisothiazol
indol
piperazinyl
dihydro
chloro
Prior art date
Application number
HR970235A
Other languages
English (en)
Inventor
Frank R Busch
Carol A Rose
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of HRP970235A2 publication Critical patent/HRP970235A2/xx
Publication of HRP970235B1 publication Critical patent/HRP970235B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HR970235A 1996-05-07 1997-05-07 Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl-6-chloro-1,3-dihydro-2h-indol-2-one HRP970235B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1653796P 1996-05-07 1996-05-07

Publications (2)

Publication Number Publication Date
HRP970235A2 HRP970235A2 (en) 1998-06-30
HRP970235B1 true HRP970235B1 (en) 2002-08-31

Family

ID=21777622

Family Applications (1)

Application Number Title Priority Date Filing Date
HR970235A HRP970235B1 (en) 1996-05-07 1997-05-07 Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl-6-chloro-1,3-dihydro-2h-indol-2-one

Country Status (46)

Country Link
US (1) US6110918A (ko)
EP (1) EP0904273B1 (ko)
JP (1) JP3102896B2 (ko)
KR (1) KR100333214B1 (ko)
CN (1) CN1092658C (ko)
AP (1) AP838A (ko)
AR (1) AR007003A1 (ko)
AT (1) ATE236902T1 (ko)
AU (1) AU730856C (ko)
BG (1) BG63601B1 (ko)
BR (1) BR9708932A (ko)
CA (1) CA2252895C (ko)
CO (1) CO4940465A1 (ko)
CZ (1) CZ289216B6 (ko)
DE (1) DE69720719T2 (ko)
DK (1) DK0904273T3 (ko)
DZ (1) DZ2221A1 (ko)
EA (1) EA001180B1 (ko)
EG (1) EG24401A (ko)
ES (1) ES2192264T3 (ko)
GT (1) GT199700042A (ko)
HK (1) HK1017893A1 (ko)
HN (1) HN1997000040A (ko)
HR (1) HRP970235B1 (ko)
HU (1) HU229057B1 (ko)
ID (1) ID17504A (ko)
IL (1) IL126590A (ko)
IS (1) IS2301B (ko)
MA (1) MA26427A1 (ko)
ME (1) ME00901B (ko)
MY (1) MY128051A (ko)
NO (1) NO312513B1 (ko)
NZ (2) NZ332219A (ko)
OA (1) OA10908A (ko)
PL (1) PL188164B1 (ko)
PT (1) PT904273E (ko)
SI (1) SI0904273T1 (ko)
SK (1) SK282674B6 (ko)
TN (1) TNSN97073A1 (ko)
TR (1) TR199802241T2 (ko)
TW (1) TW427989B (ko)
UA (1) UA47467C2 (ko)
UY (1) UY24543A1 (ko)
WO (1) WO1997042190A1 (ko)
YU (1) YU49398B (ko)
ZA (1) ZA973875B (ko)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
TW491847B (en) 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
EP0985414B1 (en) * 1998-05-26 2003-08-27 Pfizer Products Inc. Medicament for the treatment of glaucoma and ischemic retinopathy
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
MXPA02006324A (es) * 1999-12-23 2002-12-13 Pfizer Prod Inc Composiciones farmaceuticas que proporcionan concentraciones potenciadas de farmaco.
PT1468686E (pt) * 2000-06-02 2007-01-31 Pfizer Prod Inc S-metil-di-hidro-ziprasidona para o tratamento de distúrbios psiquiátricos
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR032641A1 (es) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
US8703772B2 (en) 2001-09-25 2014-04-22 Otsuka Pharmaceutical Co., Ltd. Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
UY27668A1 (es) * 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
WO2004050655A1 (en) * 2002-12-04 2004-06-17 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride
US7488729B2 (en) 2002-12-04 2009-02-10 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride salt and process for preparation thereof
MXPA05012391A (es) * 2003-05-16 2006-02-02 Pfizer Prod Inc Tratamiento de trastornos psicoticos y depresivos.
MXPA05012325A (es) * 2003-05-16 2006-01-30 Pfizer Prod Inc Procedimiento para potenciar la cognicion usando zipirasidona.
CA2525868A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Anxiety treatments with ziprasidone
US7678799B2 (en) * 2003-06-03 2010-03-16 Teva Pharmaceutical Industries Ltd. Crystalline ziprasidone HCl and processes for preparation thereof
KR20090080143A (ko) * 2003-09-02 2009-07-23 화이자 프로덕츠 인크. 지프라시돈의 지속 방출형 투여 형태
WO2005040160A2 (en) * 2003-10-24 2005-05-06 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
CN1934108A (zh) * 2003-12-18 2007-03-21 特瓦制药工业有限公司 齐拉西酮碱的多晶型b2
US20050163858A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Ziprasidone formulations
ATE451367T1 (de) * 2004-02-27 2009-12-15 Ranbaxy Lab Ltd Verfahren zur herstellung von ziprasidon
WO2006026426A2 (en) * 2004-08-27 2006-03-09 University Of Kentucky Research Foundation Amyloid peptide inactivating enzyme to treat alzheimer’s disease peripherally
ES2250001B1 (es) * 2004-09-29 2007-06-01 Medichem, S.A. Proceso para la purificacion de ziprasidona.
US7777037B2 (en) * 2004-10-27 2010-08-17 Dr. Reddy's Laboratories Limited Ziprasidone process
AU2005307797B2 (en) * 2004-11-16 2011-06-02 Alkermes Pharma Ireland Limited Injectable nanoparticulate olanzapine formulations
CA2593497A1 (en) * 2005-02-11 2006-08-17 Judith Aronhime Amorphous ziprasidone mesylate
CA2598288A1 (en) * 2005-03-03 2006-09-14 Elan Pharma International Limited Nanoparticulate compositions of heterocyclic amide derivatives
ITMI20050346A1 (it) 2005-03-07 2006-09-08 Dipharma Spa Forma solida di ziprasidone cloridrato
CA2599391A1 (en) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Crystalline forms of ziprasidone mesylate
EP1858892A1 (en) * 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd Anhydrous ziprasidone mesylate and a process for its preparation
MX2009011681A (es) * 2007-05-18 2009-11-10 Scidose Llc Formulaciones de ziprasidona.
KR100948126B1 (ko) * 2007-12-10 2010-03-18 씨제이제일제당 (주) 결정형의 지프라시돈 술폰산염, 그 제조방법, 및 그것를포함하는 약제학적 조성물
CN102234273B (zh) * 2010-04-21 2015-08-05 上海医药工业研究院 甲磺酸齐拉西酮半水合物及其制备方法
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5359068A (en) * 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one

Also Published As

Publication number Publication date
NO312513B1 (no) 2002-05-21
EA199800909A1 (ru) 1999-04-29
SK282674B6 (sk) 2002-11-06
ES2192264T3 (es) 2003-10-01
ID17504A (id) 1998-01-08
AU730856C (en) 2001-11-15
EA001180B1 (ru) 2000-10-30
KR20000010822A (ko) 2000-02-25
DE69720719T2 (de) 2003-11-06
NO985193L (no) 1998-11-06
WO1997042190A1 (en) 1997-11-13
DE69720719D1 (de) 2003-05-15
AP9700978A0 (en) 1997-07-31
ME00901B (me) 2005-11-28
IS2301B (is) 2007-10-15
TNSN97073A1 (fr) 2005-03-15
CN1216990A (zh) 1999-05-19
MA26427A1 (fr) 2004-12-20
BG63601B1 (bg) 2002-06-28
TR199802241T2 (ko) 1999-02-22
NO985193D0 (no) 1998-11-06
NZ332219A (en) 2005-02-25
YU17397A (sh) 2000-10-30
ZA973875B (en) 1998-11-06
CZ289216B6 (cs) 2001-12-12
CO4940465A1 (es) 2000-07-24
YU49398B (sh) 2005-11-28
OA10908A (en) 2001-10-26
EG24401A (en) 2009-04-29
HU229057B1 (en) 2013-07-29
PL188164B1 (pl) 2004-12-31
HRP970235A2 (en) 1998-06-30
IL126590A (en) 2001-11-25
BR9708932A (pt) 1999-08-03
IL126590A0 (en) 1999-08-17
KR100333214B1 (ko) 2002-06-20
BG102893A (en) 1999-09-30
JP3102896B2 (ja) 2000-10-23
US6110918A (en) 2000-08-29
ATE236902T1 (de) 2003-04-15
IS4878A (is) 1998-10-23
PL329880A1 (en) 1999-04-12
HK1017893A1 (en) 1999-12-03
CN1092658C (zh) 2002-10-16
EP0904273B1 (en) 2003-04-09
AU730856B2 (en) 2001-03-15
CA2252895C (en) 2002-08-20
UA47467C2 (uk) 2002-07-15
UY24543A1 (es) 2000-09-29
JPH11509865A (ja) 1999-08-31
GT199700042A (es) 1998-10-02
AP838A (en) 2000-05-03
HUP9902808A2 (hu) 2000-03-28
DK0904273T3 (da) 2003-07-07
SK150598A3 (en) 2000-03-13
HUP9902808A3 (en) 2000-04-28
SI0904273T1 (en) 2003-08-31
CA2252895A1 (en) 1997-11-13
AU1936897A (en) 1997-11-26
DZ2221A1 (fr) 2002-12-03
AR007003A1 (es) 1999-10-13
NZ508303A (en) 2001-07-27
MY128051A (en) 2007-01-31
HN1997000040A (es) 1997-06-05
EP0904273A1 (en) 1999-03-31
PT904273E (pt) 2003-06-30
TW427989B (en) 2001-04-01
CZ349498A3 (cs) 1999-09-15

Similar Documents

Publication Publication Date Title
HRP970235B1 (en) Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl-6-chloro-1,3-dihydro-2h-indol-2-one
HRP970236A2 (en) Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
IL106777A0 (en) Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride
AP9901696A0 (en) Composition comprising 5-(4-(2-(N-methyl-N-2-pyridyl)amino) ehtoxy benzyl)thiazolidine-2,4-dione
HU9802874D0 (en) Process for making 2-(methylthio)-5-(trifluoromethyl)-1,3,4-thiadiazole using methyldithiocarbazinate
PL376721A1 (pl) Pochodne acylowe 5-(2-(4-(1,2-benzoizotiazol-3-ilo)-1-piperazynylo) etylo)-6-chloro-1,3-dihydro-2H-indol-2-onu o działaniu neuroleptycznym
HUP9802877A3 (en) Process for producing 2-(methylsulfonyl)-5-(trifluoromethyl)-1,3,4-thiadiazole
HUP9902404A3 (en) Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-choloro-1,3-dihydro-2(2h)-indol-2-one (-ziprasidone), its preparation and its use as dopamine d2 antagonist
SI1556378T1 (sl) Acilni derivati 5-(2-(4-(1,2-benzizotiazol-3-il)-1-piperaznil)etil)-6-kloro-1,3-dihidro -2H-indol-2-ona z nevrolepticno aktivnostjo
IL166189A (en) 5-{4-[2-(n-methyl-n-(2-pyridyl) amino) ethoxy] benzyl}-5-{1-[2, 4-dioxothiazolidine-5-yl]-1-[4-(2-(n-methyl-n-(2-pyridyl) amino) ethoxy) phenyl] methyl}-2,4-thiazolidinedione and tautomeric form, salt or solvate thereof
MY109504A (en) Monohydrate of 5-(2-(4-(1,2 benzisothiazol-3-yl)-1- piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2- one hydrochloride

Legal Events

Date Code Title Description
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
A1OB Publication of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20160503

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20170507